Julia Vry1, Isabel J Schubert2, Oliver Semler3, Verena Haug2, Eckhard Schönau3, Janbernd Kirschner2. 1. Department of Paediatrics and Adolescent Medicine, University Medical Centre Freiburg, Mathildenstraße 1, 79106 Freiburg, Germany. Electronic address: Julia.vry@uniklinik-freiburg.de. 2. Department of Paediatrics and Adolescent Medicine, University Medical Centre Freiburg, Mathildenstraße 1, 79106 Freiburg, Germany. 3. Children's Hospital University Cologne, Germany.
Abstract
INTRODUCTION: Whole-body-vibration training is used to improve muscle strength and function and might therefore constitute a potential supportive therapy for neuromuscular diseases. OBJECTIVE: To evaluate safety of whole-body vibration training in ambulatory children with Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). METHODS: 14 children with DMD and 8 with SMA underwent an 8-week vibration training programme on a Galileo MedM at home (3 × 3 min twice a day, 5 days a week). Primary outcome was safety of the training, assessed clinically and by measuring serum creatine kinase levels. Secondary outcome was efficacy as measured by changes in time function tests, muscle strength and angular degree of dorsiflexion of the ankles. RESULTS: All children showed good clinical tolerance. In boys with DMD, creatine kinase increased by 56% after the first day of training and returned to baseline after 8 weeks of continuous whole-body vibration training. No changes in laboratory parameters were observed in children with SMA. Secondary outcomes showed mild, but not significant, improvements with the exception of the distance walked in the 6-min walking test in children with SMA, which rose from 371.3 m to 402.8 m (p < 0.01). INTERPRETATION: Whole-body vibration training is clinically well tolerated in children with DMD and SMA. The relevance of the temporary increase in creatine kinase in DMD during the first days of training is unclear, but it is not related to clinical symptoms or deterioration.
INTRODUCTION: Whole-body-vibration training is used to improve muscle strength and function and might therefore constitute a potential supportive therapy for neuromuscular diseases. OBJECTIVE: To evaluate safety of whole-body vibration training in ambulatory children with Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). METHODS: 14 children with DMD and 8 with SMA underwent an 8-week vibration training programme on a Galileo MedM at home (3 × 3 min twice a day, 5 days a week). Primary outcome was safety of the training, assessed clinically and by measuring serum creatine kinase levels. Secondary outcome was efficacy as measured by changes in time function tests, muscle strength and angular degree of dorsiflexion of the ankles. RESULTS: All children showed good clinical tolerance. In boys with DMD, creatine kinase increased by 56% after the first day of training and returned to baseline after 8 weeks of continuous whole-body vibration training. No changes in laboratory parameters were observed in children with SMA. Secondary outcomes showed mild, but not significant, improvements with the exception of the distance walked in the 6-min walking test in children with SMA, which rose from 371.3 m to 402.8 m (p < 0.01). INTERPRETATION: Whole-body vibration training is clinically well tolerated in children with DMD and SMA. The relevance of the temporary increase in creatine kinase in DMD during the first days of training is unclear, but it is not related to clinical symptoms or deterioration.
Authors: Vanessa Rustler; Julia Däggelmann; Fiona Streckmann; Wilhelm Bloch; Freerk T Baumann Journal: Support Care Cancer Date: 2018-10-27 Impact factor: 3.603
Authors: A Schwarz; C Pick; R Harrach; G Stein; H Bendella; O Ozsoy; U Ozsoy; E Schoenau; P Jaminet; L Sarikcioglu; S Dunlop; D N Angelov Journal: J Musculoskelet Neuronal Interact Date: 2015-06 Impact factor: 2.041
Authors: Eloá Moreira-Marconi; Danubia C Sá-Caputo; Carla F Dionello; Eliane O Guedes-Aguiar; Cintia R Sousa-Gonçalves; Danielle S Morel; Laisa L Paineiras-Domingos; Patricia L Souza; Cristiane R Kütter; Rebeca G Costa-Cavalcanti; Glenda Costa; Patricia C Paiva; Claudia Figueiredo; Samuel Brandão-Sobrinho-Neto; Christina Stark; Marianne Unger; Mario Bernardo-Filho Journal: Afr J Tradit Complement Altern Med Date: 2017-07-07
Authors: Anna Petryk; Lynda E Polgreen; Molly Grames; Dawn A Lowe; James S Hodges; Peter Karachunski Journal: Muscle Nerve Date: 2017-02-06 Impact factor: 3.217